Relmada Therapeutics Inc. (NASDAQ:RLMD) previous close was $36.03 while the outstanding shares total 16.05M. The firm has a beta of 0.30. RLMD’s shares traded higher over the last trading session, gaining 1.22% on 02/12/21. The shares fell to a low of $34.37 before closing at $36.47. Intraday shares traded counted 79461.0, which was -4.53% lower than its 30-day average trading volume of 76.02K. The stock’s Relative Strength Index (RSI) is 57.99, with weekly volatility at 4.74% and ATR at 1.79. The RLMD stock’s 52-week price range has touched low of $23.25 and a $54.00 high.
Investors have identified the Drug Manufacturers – Specialty & Generic company Relmada Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $585.34 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Relmada Therapeutics Inc. (RLMD) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 125.47 million total, with 3.39 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -4.83 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on RLMD sounds very interesting.
Is the stock of RLMD attractive?
In related news, CEO, TRAVERSA SERGIO sold 1,930 shares of the company’s stock in a transaction that recorded on Feb 10. The sale was performed at an average price of 35.28, for a total value of 68,097. As the sale deal closes, the CFO, Shenouda Maged now sold 2,410 shares of the company’s stock, valued at 84,825. Also, CFO, Shenouda Maged sold 5,359 shares of the company’s stock in a deal that was recorded on Feb 09. The shares were price at an average price of 35.24 per share, with a total market value of 188,843. Following this completion of acquisition, the CEO, TRAVERSA SERGIO now holds 5,963 shares of the company’s stock, valued at 209,939. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.70%.
5 out of 6 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Relmada Therapeutics Inc.. 0 analysts has assigned a Sell rating on the RLMD stock. The 12-month mean consensus price target for the company’s shares has been set at $62.83.